Health Blueprint

Back to Longevity News

News summary

Santo Therapeutics Receives FDA IND Clearance for Gene Therapy to treat rare genetic condition causing tumours to grow on nerves

Source: Stevenage Bioscience Catalyst • Published: 30 Oct 2026, 09:00

Summarized by Masters of Longevity from Stevenage Bioscience Catalyst.

FDA cleared an IND for ST002, enabling U.S. Phase Ib/II testing.

Santo Therapeutics Receives FDA IND Clearance for Gene Therapy to treat rare genetic condition causing tumours to grow on nerves
Key Takeaways
  • ST002 is an investigational lentiviral NF2 gene therapy.
  • The IND clearance allows a Phase Ib/II trial to proceed.
  • Preclinical and exploratory data showed tumour growth inhibition.
Read the full article at Stevenage Bioscience Catalyst ↗

Continue exploring

Recommended MoL Picks

MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickCan You Really Measure Whether You’re Aging More Slowly?A younger epigenetic-age score can look like proof that an intervention is working. A major new analysis shows which clocks detect change—and why movement is not yet the same as longer healthspan.